Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,902 people get AEZS articles and Market Currents by email alert.
Get email alerts on AEZS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in TorontoPR Newswire (Wed, 7:30AM)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 7, 2013)
-
Æterna Zentaris Inc. - Shareholder/Analyst CallThu, Apr 25
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 15, 2013)
-
PR Newswire (Mar 21, 2013)
-
-
Stock Watch Wednesday, 20 March 2013VFC's Stock House • Wed, Mar 20 -
PR Newswire (Mar 13, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
A Dismal 2012 May Make For A Good Entry Now For AEterna ZentarisChemistfrog • Tue, Nov 13, 2012
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Stock Watch Wednesday, 20 March 2013VFC's Stock House • Wed, Mar 20
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Æterna Zentaris Inc. - Shareholder/Analyst CallThu, Apr 25
-
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in TorontoPR Newswire (Wed, 7:30AM)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 15, 2013)
-
PR Newswire (Mar 21, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Feb 20, 2013)
-
at CNBC.com (Jan 9, 2013)
-
PR Newswire (Dec 4, 2012)
-
PR Newswire (Nov 26, 2012)
AEZS vs. ETF Alternatives
Company Description
Currently, there's no company description for AEZS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 4:02 PM Aeterna Zentaris (AEZS +1.6%) moves up after posting a better than expected Q1. Zacks upgraded the shares to Outperform from Neutral on the back of the report with a price target of $2.10. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, May 7, 7:18 PM Aeterna Zentaris (AEZS): Q1 EPS of $0.07. Revenue of $16.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, April 17, 12:44 PM AEterna Zentaris (AEZS -2%) says it's agreed to transfer rights and grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA. It will receive a one-time payment of about $3.2M for the transaction, as well as certain other payments to execute a 36-month transitional services agreement to provide various transition services to assist Merck KGaA in assuming responsibility for manufacturing. Comment! [Healthcare, On the Move]
- Monday, April 15, 11:30 AM AEterna Zentaris (AEZS -0.6%) appoints David A. Dodd as it's new president and CEO, succeeding Juergen Engel. Dodd was also appointed as a member of the company's board of directors. Comment! [Healthcare]
-
Thursday, April 11, 9:10 AM
Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move] - Wednesday, April 10, 7:51 PM Aeterna Zentaris (AEZS) issues updated proof-of-concept results for its tumor treating Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138. The company says results showed the compounds have high potential for the treatment of luteinizing hormone-releasing hormone receptor positive tumors, particularly in human ovarian and endometrial cancer xenograft models. Shares +19% AH. Comment! [Healthcare, On the Move]
-
Wednesday, April 10, 6:15 PM
After-hours top gainers, as of 5:45 p.m.: AEZS +29%. ZUMZ +10%. PCYG +4%. BLK +4%. MDU +3%.
After-hours top losers: FTNT -15%. APOG -7%. EQIX -4%. FIRE -4%. YUM -3%. Comment! [On the Move] - Wednesday, April 10, 8:39 AM Aeterna Zentaris (AEZS) signs an agreement with Ergomed to carry out Phase III trials of Aeterna's AEZS-108 drug to treat endometrial cancer, the most common gynecologic malignancy. Ergomed will bear 30% of the costs, which are pegged at $30M, and conduct the study, as well as receive a share of any profits. (PR) Comment! [Healthcare]
- Thursday, March 21, 5:24 PM More on Aeterna Zentaris (AEZS): Q4 beats consensus estimates on both its EPS loss as well revenue. Total sales declined 24% Y/Y, mainly due to the recording of a $2.6M milestone payment from Yakult for the initiation of Phase 1 trials for perifosine in Japan during Q411. Operational expenses declined due to lower employee compensation and benefit costs and a reduced headcount at the drug developer. 2 Comments [Healthcare, Earnings]
- Thursday, March 21, 4:24 PM Aeterna Zentaris (AEZS): Q4 EPS of -$0.29. Revenue of $9.5M . (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Monday, March 11, 12:56 PM
Midday top 10 gainers: CALI +52%. BOSC +45%. ESYS +30%. CBMX +25%. LAS +25%. PAMT +15%. FONR +15%. SCR +15%. SGOC +15%. RWC +14%.
Midday top 10 losers: AEZS -21%. NSU -11%. CSIQ -11%. SPEX -11%. FREE -10%. DKS -10%. CERE -10%. CNIT -9%. ONP -9%. RDCM -8%. Comment! [On the Move] - Monday, March 11, 12:13 PM Shares of Aetna Zentaris (AEZS) continue to plunge since their resumption of trading, now down 29% at $1.86 after an independent data safety monitoring board recommended discontinuing ongoing Phase 3 studies of perifosine. Comment! [Healthcare, On the Move]
- Monday, March 11, 11:47 AM Aeterna Zentaris (AEZS) resumes trading -10%. Comment! [Healthcare, On the Move]
- Monday, March 11, 11:33 AM Trading in Aeterna Zentaris (AEZS) will resume at 11:45 AM ET. Comment! [Healthcare]
- Monday, March 11, 11:29 AM Shares of Aeterna Zentaris (AEZS -1.9%) remain halted after the company says an independent Data Safety Monitoring Board has recommended discontinuing ongoing Phase 3 studies comparing the efficacy and safety of perifosine in patients with relapsed or relapsed/refractory multiple myeloma. Based on its analysis, the DSMB reported that it was highly unlikely the study would achieve a significant difference in its primary endpoint. Comment! [Healthcare, On the Move]
- Tuesday, January 29, 3:23 PM Shares of AEterna Zentaris (AEZS +18.5%) shares rocket higher in afternoon trading on the back of cancer drug peer Keryx Pharmaceuticals (KERX +40%) big gains. Volumes are extremely high in AEZS today, with over 4M shares changing hands, compared to the daily average of around 850K. 3 Comments [Healthcare, On the Move]
-
Ryan Mallory
Fuinhaz Setups for April 11 2013 | $AEZS $AMRS $ASML $CETV $GRPN $NFLX $VOD $ZNGA | http://bit.ly/YNtwJP - View all 0 replies
-
VFC's Stock House
$AEZS - Many gave Perifisone no chance after $KERX failure... Monday action likely the result of opportune shorts. http://bit.ly/cAHZ42 - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
Michael Webb: mr. lynch, glad you caught on. i noticed the trend months ago. it does however depend on which expert. bret jensen bump is the best.
-
- View all 0 replies
-
- View all 2 replies
-
-
mr.lynch: RESEARCH RESEARCH RESEARCH then put your profit into techs energy & real estate
-
- View all 1 replies
-
Perkins Cove: Sell @ $2.70 (9:40), 5% gain. Sorry for posting delay.
-
smokeyRose
Bought CLNE should have done that yesterday! sold a couple losers KERX & AEZS bunch of losers!!!! hope after pres speaks CLNE will JUMP!! - View all 0 replies
-
- View all 0 replies
-
VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY - View all 1 replies
-
LATEST REPLIES
-
- View all 1 replies
-
Michael Webb: mr. lynch, glad you caught on. i noticed the trend months ago. it does however depend on which expert. bret jensen bump is the best.
-
- View all 2 replies
-
-
mr.lynch: RESEARCH RESEARCH RESEARCH then put your profit into techs energy & real estate
-
- View all 1 replies
-
Perkins Cove: Sell @ $2.70 (9:40), 5% gain. Sorry for posting delay.
-
VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY - View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 10 replies
-
onehardroll: Phemale60, it's still going down......when will we know if it's approved or not? -
-
The Scientist
KERX should not have given away perifosine rights to AEZS. Strongest data is for r/r MM. Study headed by Dr. Richardson at Dana-Farber - View all 1 replies
-
The Scientist: Dr Richardson director of MM at Dana-F. He is not dumb enough to waste his time-effort if perifosine had NO possible chance of working
-
- View all 1 replies
-
-
- View all 2 replies
-
hotnutsjesus: lol, it went up because of the Jeremy Richards article and then the validity of the article/author was questioned. Looks kinda like a pump -
-
- View all 3 replies
-
sstonerm3: MovA, I added to my COSWF last October under $21. Getting close to time to get some more me thinks. -
-
Michael Bryant
AEterna Zentaris' (AEZS) chart shows impressive support/resistance. Just from chart, one can guess stock will go up http://yhoo.it/yrhLvO - View all 2 replies
-
Funkengruven: It's been awhile... hopefully good things come to those that wait! -
-
- View all 1 replies
-
Andreas Braun: the more effective perifosine is the longer it takes to come to the 360th event
-
The Scientist
If AEZS's perifosine had absolutely no effect or was detrimental to colon CA patients, the DSMB would have stopped the trial in August. - View all 1 replies
-
-
- View all 1 replies
-